Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 7
2008 6
2009 2
2010 1
2011 2
2012 4
2013 8
2014 11
2015 11
2016 11
2017 15
2018 9
2019 11
2020 9
2021 11
2022 12
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.
Kammerer-Jacquet SF, Deleuze A, Saout J, Mathieu R, Laguerre B, Verhoest G, Dugay F, Belaud-Rotureau MA, Bensalah K, Rioux-Leclercq N. Kammerer-Jacquet SF, et al. Among authors: verhoest g. Int J Mol Sci. 2019 Apr 4;20(7):1692. doi: 10.3390/ijms20071692. Int J Mol Sci. 2019. PMID: 30987368 Free PMC article. Review.
Immunotherapy in Renal Cell Carcinoma: The Future Is Now.
Deleuze A, Saout J, Dugay F, Peyronnet B, Mathieu R, Verhoest G, Bensalah K, Crouzet L, Laguerre B, Belaud-Rotureau MA, Rioux-Leclercq N, Kammerer-Jacquet SF. Deleuze A, et al. Among authors: verhoest g. Int J Mol Sci. 2020 Apr 5;21(7):2532. doi: 10.3390/ijms21072532. Int J Mol Sci. 2020. PMID: 32260578 Free PMC article. Review.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
Prognostic factors for upper urinary tract urothelial carcinoma.
Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF. Chromecki TF, et al. Among authors: verhoest g. Nat Rev Urol. 2011 Jul 5;8(8):440-7. doi: 10.1038/nrurol.2011.96. Nat Rev Urol. 2011. PMID: 21727942 Review.
[Angiotensin-2 type 1 receptors (AT1R) and cancers].
Dolley-Hitze T, Verhoest G, Jouan F, Le Pogamp P, Arlot-Bonnemains Y, Oger E, Belaud-Rotureau MA, Rioux-Leclercq N, Vigneau C. Dolley-Hitze T, et al. Among authors: verhoest g. Nephrol Ther. 2013 Apr;9(2):85-91. doi: 10.1016/j.nephro.2012.09.006. Epub 2013 Jan 14. Nephrol Ther. 2013. PMID: 23332110 Review. French.
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial.
Lebret T, Paoletti X, Pignot G, Roumiguié M, Colombel M, Savareux L, Verhoest G, Guy L, Rigaud J, De Vergie S, Poinas G, Droupy S, Kleinclauss F, Courtade-Saïdi M, Piaton E, Radulescu C, Rioux-Leclercq N, Kandel-Aznar C, Renaudin K, Cochand-Priollet B, Allory Y, Nivet S, Rouprêt M. Lebret T, et al. Among authors: verhoest g. World J Urol. 2023 Sep;41(9):2381-2388. doi: 10.1007/s00345-023-04519-4. Epub 2023 Jul 22. World J Urol. 2023. PMID: 37480491 Free PMC article.
103 results